Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,883 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A. Bendell JC, et al. Among authors: jones s. Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2. Br J Cancer. 2017. PMID: 28152546 Free PMC article. Clinical Trial.
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T, Von Hoff DD. Rinaldi DA, et al. Among authors: jones s. Cancer Chemother Pharmacol. 1999;44(5):372-80. doi: 10.1007/s002800050992. Cancer Chemother Pharmacol. 1999. PMID: 10501910 Clinical Trial.
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL. Burris HA 3rd, et al. Among authors: jones sf. J Clin Oncol. 2005 Aug 10;23(23):5305-13. doi: 10.1200/JCO.2005.16.584. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955900 Clinical Trial.
A Phase I trial of protracted oral fixed-dose temozolomide.
Jones SF, Greco FA, Gian VG, Miranda FT, Raefsky EL, Hainsworth JD, Willcutt NT, Beschorner AF, Kennerly G, Burris HA 3rd. Jones SF, et al. Cancer. 2005 Nov 1;104(9):1985-91. doi: 10.1002/cncr.21408. Cancer. 2005. PMID: 16134182 Free article. Clinical Trial.
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR. Fracasso PM, et al. Clin Cancer Res. 2007 Feb 1;13(3):986-93. doi: 10.1158/1078-0432.CCR-06-1542. Clin Cancer Res. 2007. PMID: 17289894 Clinical Trial.
11,883 results
You have reached the last available page of results. Please see the User Guide for more information.